MEDICINA
Departamento
University of Freiburg
Friburgo de Brisgovia, AlemaniaPublicaciones en colaboración con investigadores/as de University of Freiburg (23)
2024
-
Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells
Science Immunology, Vol. 9, Núm. 91
-
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation
Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94
2023
-
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188
2022
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
2021
-
A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net
Journal of Inherited Metabolic Disease, Vol. 44, Núm. 5, pp. 1124-1135
-
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507
-
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
The Lancet Haematology, Vol. 8, Núm. 3, pp. e194-e204
-
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Leukemia, Vol. 35, Núm. 1, pp. 31-44
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 283-306
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
-
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
Leukemia, Vol. 34, Núm. 8, pp. 2000-2011
2019
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973
-
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
The Lancet Haematology, Vol. 6, Núm. 12, pp. e638-e649
-
Mars: Mutation-adjusted risk score for advanced systemic mastocytosis
Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2846-2856
-
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Haematologica, Vol. 104, Núm. 5, pp. 929-936
-
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Haematologica, Vol. 104, Núm. 10, pp. 1935-1949
-
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106
2018
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560
2017
-
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
Oncotarget, Vol. 8, Núm. 43, pp. 73483-73500